Prof. Christopher Bowman's group has designed a novel thioester monomer system that can be seamlessly incorporated into existing polymerization procedures and allows for extremely rapid, room-temperature plasticity under ambient conditions, offering a route towards recycling and remolding.
Researchers working at CU Boulder and NIST have developed an electroplated rhenium film that is superconducting at relatively high critical temperatures of up to 6K, which is well above the boiling point of liquid helium, making the critical temperature easy to obtain.
Researchers working at CU Boulder and Immodulon Therapeutics Limited have discovered novel, mycobacterially-derived lipid compounds that have potent anti-inflammatory effects and could be useful in the treatment and prevention of sepsis and post-sepsis syndrome.
Prof. Dejan Filipovic’s team has developed an effective new configuration for a Simultaneous Transmit and Receive (STAR) antenna system that makes it a unique candidate for military and civilian applications.
Dr. Amy Palmer's team is developing Riboglow, a versatile riboswitch-based RNA imaging system. The short size of the RNA tag used in the system enabled the visualization of U1 snRNA in live cells for the first time.
Dr. Christoph Keplinger and his lab team have developed breakthrough actuators for robots: soft, self-healing “artificial muscles” that mimic the strength, speed and diversity of motion of real muscle, capable of grasping delicate objects and more.
CU Boulder researchers have designed a micro-chip scale circulator that allows simultaneous transmission and reception in a single channel, doubling the bandwidth of communication systems without magnets.
Professor Mark Hernandez has developed a cement admixture material that uses pH-responsive heavy metal toxicity to impair the growth of microorganisms that cause corrosion of concrete wastewater infrastructure. The low-cost admixture can also increase both the compressive and tensile strength of the concrete.
Professor Ding Xue has discovered a critical factor in the signalling between irradiated and non-irradiated cells. A series of preclinical drugs are being developed with the goal of improving patient response to radiation therapy.
The Insider is Venture Partners at CU Boulder's monthly newsletter featuring the latest headlines, news, events, opportunities and emerging innovations coming out of the university. We have several editions for our audiences: